Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Synopsys Completes Acquisition Of ExpertIO

RELATED NEWS
Trade SNPS now with 

Technology company Synopsys, Inc. (SNPS: Quote) Monday announced that it acquired ExpertIO, Inc., an independent provider of verification IP, or VIP, for industry standard protocols. The terms of the deal were not disclosed.

Manoj Gandhi, General Manager of Synopsis Verification Group, commented, "By acquiring ExpertIO, Synopsys adds a new set of storage protocols to our expanding VIP portfolio, plus an experienced team of development experts to help us drive the next level of innovation in VIP technology."

ExpertIO's entire team of engineers will join Synopsys' Verification Group. The Founder and Chief Executive Officer of ExpertIO, Craig Stoops, will join the Synopsys team as a technical leader helping drive Synopsys' VIP roadmap.

With leading SoC designs deploying more complex protocols, VIP has become a critical component of the verification environment. VIP provides functional models of on- and off-chip protocols that verification engineers use to test all of the interfaces on an SoC before manufacturing.

Click here to receive FREE breaking news email alerts for Synopsys Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Bundesbank President Jens Weidmann has criticized the European Central Bank's latest measures to boost the euro area economy, such as the planned purchases of covered bonds and asset-backed securities and covered bonds, as well as the interest rate reduction this month. The latest decisions suggest... European stocks are seen opening lower on Monday, tracking weak commodity prices and a subdued trend across the Asia-Pacific region as investors look ahead to Chinese manufacturing data due on Tuesday for important clues about China's growth outlook. China is experiencing stable growth and there... Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.